Format

Send to

Choose Destination
PLoS One. 2014 Oct 14;9(10):e109768. doi: 10.1371/journal.pone.0109768. eCollection 2014.

Neurologic abnormalities in mouse models of the lysosomal storage disorders mucolipidosis II and mucolipidosis III γ.

Author information

1
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
2
Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America.
3
Diabetic Cardiovascular Disease Center, Washington University School of Medicine, St. Louis, Missouri, United States of America.
4
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
5
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America.

Erratum in

  • PLoS One. 2014;9(11):e114199.

Abstract

UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase is an α2β2γ2 hexameric enzyme that catalyzes the synthesis of the mannose 6-phosphate targeting signal on lysosomal hydrolases. Mutations in the α/β subunit precursor gene cause the severe lysosomal storage disorder mucolipidosis II (ML II) or the more moderate mucolipidosis III alpha/beta (ML III α/β), while mutations in the γ subunit gene cause the mildest disorder, mucolipidosis III gamma (ML III γ). Here we report neurologic consequences of mouse models of ML II and ML III γ. The ML II mice have a total loss of acid hydrolase phosphorylation, which results in depletion of acid hydrolases in mesenchymal-derived cells. The ML III γ mice retain partial phosphorylation. However, in both cases, total brain extracts have normal or near normal activity of many acid hydrolases reflecting mannose 6-phosphate-independent lysosomal targeting pathways. While behavioral deficits occur in both models, the onset of these changes occurs sooner and the severity is greater in the ML II mice. The ML II mice undergo progressive neurodegeneration with neuronal loss, astrocytosis, microgliosis and Purkinje cell depletion which was evident at 4 months whereas ML III γ mice have only mild to moderate astrocytosis and microgliosis at 12 months. Both models accumulate the ganglioside GM2, but only ML II mice accumulate fucosylated glycans. We conclude that in spite of active mannose 6-phosphate-independent targeting pathways in the brain, there are cell types that require at least partial phosphorylation function to avoid lysosomal dysfunction and the associated neurodegeneration and behavioral impairments.

PMID:
25314316
PMCID:
PMC4196941
DOI:
10.1371/journal.pone.0109768
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center